Abstract library

1169 results for "data base".
#107 Results of the Gastroenteropancreatic NETs Spanish Registry in the 2001-2010 period
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEPNETs) are infrequent and heterogeneous neoplasms that have conditioned the lack of verified epidemiologic data.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Jaume Capdevila
#2221 Trends in Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in India: A Report of Multicentre Data from a Web Based Registry
Introduction: The gastroenteropancreatic neuroendocrine tumors (GEP- NETs) are rare tumors with lack of population-based data especially from India.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Gunjan Desai
Authors: Desai G, Pande P, Mansukhani V, Shah R, ...
#2968 Incidence of Rectal NEN and Adherence to Pathology Classification Rules and Treatment Guidelines: Results of the Population Based Cancer Registry in Belgium
Introduction: Classification of rectal NEN (rNEN) changed significantly over the years.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Karen Geboes
#3002 Quality of Life, Tumour Heterogeneity and Biomarker Levels in Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours: Baseline Data from CLARINET FORTE
Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof. Philippe Ruszniewski
#1583 The Clinical Pathological Characteristics and Prognostic Factors of Rectal Neuroendocrine Tumors- A Retrospective Analysis Based on Multi Center Data
Introduction: The pathological characteristics and prognosis factors of rectum neuroendocrine tumor still have a lot of uncertainty.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Wei Gengzhou
Authors: Gengzhou W, Wei W, Xingyu F, ...
#2178 Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumor: Preliminary Baseline Characteristics from the Nutrition in NETs Study
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP NET) cause various symptoms impacting on nutritional status and diet. Published data indicates up to 25% of GEP NET patients are malnourished, and dietary change is prevalent. Further research is required to guide nutrition recommendations.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Erin Kennedy
Authors: Kennedy E, Kiss N, Michael M, Gough K, ...
#3041 Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database
Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: PhD Delphine Gueguen
#994 Predictive Biomarkers of Response in Patients with Extrapulmonary Neuroendocrine Tumors (EPNET) Treated with Platin-based Chemotherapy
Introduction: EPNET, particularly advanced and Grade 3 (G3) tumors are often treated with chemotherapy. While many patients experience tumor response, those rarely live for more than two years. Predictive markers could potentially help us to tailor the best treatment for these patients (pts).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: MD Juliana F Rego
#1147 Correlation of Serum Plasma Chromogranin A with Survival and Disease Features in Patients with Gastroenteropancreatic Neuroendocrine Tumors. First Results in a Large Database in Argentina. ARGENTUM GROUP.
Introduction: The plasma chromogranin A (CgA) is the best general biomarker in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). CrA levels are elevated in a variety of GEP-NETs and are used to aid in diagnosis, prognosis, and monitoring of treatment effects in this population.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Juan Manuel O'Connor
Authors: Belli S, O'Connor J M, Oneto A, Pesce V, ...
#1634 Trends of Incidence and Survivals for Gastric Neuroendocrine Neoplasms: An Analysis of 3523 Patients in the SEER Database
Introduction: The published evidence on gastric neuroendocrine neoplasms (g-NENs) is often based on small series of patients.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Huang Chang-Ming